RxDoctor Payments Data

Huy Nguyen, MD

Family Medicine · Cypress, TXNPI 1952469819

Payments from drug & device makers

$12,929in general payments, 2019–2025

Across 670 payments — averaging $19.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Amgen$982
  • Bayer$875
  • Boehringer Ingelheim$686
  • Pfizer$573
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$12,83299%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,929 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$96,277
Medicare patients
242
Services billed
1,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide49$104,661
FarxigaDapagliflozin Propanediol62$70,713
OzempicSemaglutide46$68,700
JardianceEmpagliflozin31$51,364
VascepaIcosapent Ethyl39$28,231
ProliaDenosumab16$27,581
MounjaroTirzepatide18$20,735
JanuviaSitagliptin Phosphate13$20,456
TrulicityDulaglutide14$19,091
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$16,688
SymbicortBudesonide/Formoterol Fumarate19$6,488
Rosuvastatin Calcium233$3,384
Levothyroxine Sodium255$2,886
SynthroidLevothyroxine Sodium26$2,404
Losartan Potassium212$2,199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,346$173,36195 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,198$93,888105 claims
Boehringer IngelheimJardiance$686$51,36431 claims
Lilly USA, LLCMounjaro, Trulicity$455$39,82632 claims
AmgenProlia$982$27,58116 claims
MerckJanuvia$169$20,45613 claims
AbbVieSynthroid$434$2,40426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →